Iperion Limited Analysis

Overview

Iperion Limited (formally Southern Charter Financial Group Limited) is in the process of commercializing a novel antimicrobial coating product, being marketed under the name Pathoglaze. Early in 2023 Iperion entered into a license agreement granting the company an exclusive, worldwide, sub-licensable licence to manufacture, use, sell, distribute, import and export a self-cleaning, transparent, antimicrobial, surface coating product. A pilot manufacturing facility has since been established in Malaysia. The manufacturing facility and production is fully outsourced. The company is now actively marketing Pathoglaze.

Prior to 2023 the company did not have an operating business, but was searching for and investigating opportunities for acquiring a new business. This followed the completion of transactions on 31 August 2017 that injected cash, introduced a new controlling shareholder and spun-out all previous assets, liabilities and business operations.

Performance

The following information was extracted from Iperion Limited's full year results, released 29 May 2025.

Financial Results

The Company reported a net loss attributable to shareholders of $444,433 for the year. This compares with a net loss attributable to shareholders of $822,259 for the previous year.

The manufacturing plant expense for the year was $150,000. This is significantly less than the $500,000 incurred in the prior year. The prior year consisted of $100,000 for the establishment of the manufacturing facility and $400,000 for the fixed annual facility and operating fees. The Company received a discount of $350,000 on the fixed fee for the 2025 year in recognition of lower than expected production activity and the plant being partially supported by research grants secured by the Operator, Three Summit Ventures, on the ongoing development in applications for the Pathoglaze product.

Three Summit Ventures has also agreed to fully discount the agreed $400,000 fixed fee for the next financial year ending March 2026. Fees required to support direct production costs may still be payable when sales activities commence. Administrative expenses for the year were $306,531 decreasing by $47,841 on the prior year.

Expenses remained mostly in line with the previous year, except for stock exchange costs that were lower this year and the previous year included higher costs for international trade fairs.